Dr. Reddy’s Announces the Launch of Donepezil Hydrochloride Tablets, 23 mg

  Dr. Reddy’s Announces the Launch of Donepezil Hydrochloride Tablets, 23 mg

Business Wire

HYDERABAD, India -- July 28, 2013

Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has launched
Donepezil Hydrochloride Tablets, 23 mg, a therapeutic equivalent generic
version of ARICEPT^®, 23 mg in the U.S. market on July 26, 2013, following the
approval by the United States Food & Drug Administration (USFDA) of Dr.
Reddy’s ANDA for Donepezil Hydrochloride Tablets, 23 mg.

The ARICEPT^®, 23 mg brand had U.S. sales of approximately $92.6 Million MAT
for the most recent twelve months ending in May 2013 according to IMS Health*.

Dr. Reddy’s Donepezil Hydrochloride Tablets, 23 mg is available in bottle
count sizes of 30 and 90.


This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infective. Major markets
include India, USA, Russia-CIS and Europe apart from other select geographies
within Emerging Markets.

For more information, log on to: www.drreddys.com

ARICEPT^® is a trademark used by Eisai Inc. under license from Eisai R&D
Management Co., Ltd.
*IMS National Sales Perspectives: Retail and Non-Retail MAT May 2013


Dr. Reddy’s Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
Saunak Savla, +91-40-49002135
Milan Kalawadia (USA), +1 908-203-4931
S Rajan, +91-40-49002445
Press spacebar to pause and continue. Press esc to stop.